Document is current

Article History

Received: 30 August 2022

Accepted: 5 December 2022

First Online: 3 January 2023

Declarations

:

: RGR reports research grants from Pfizer related to this submitted work, and research grants from Pfizer and Brazilian Ministry of Health and lectures fees from Novartis outside of this submitted work. CAP declares research grants from National Institute for Health Technology Assessment, FAPERGS, CNPq, and Brazilian Ministry of Health (PROADI-SUS), and consultant and lecture fees from Novartis, Roche, Bayer, Bristol-Meyers-Squibb, Amgen, Pfizer, Astrazeneca outside of this submitted work. LKD reports research grants from Brazilian Ministry of Health (PROADI-SUS), Boehringer Ingelheim, Bristol-Myers-Squibb and consulting fees from Lilly, Roche and Gilead outside of this submitted work. FGZ reports research grants from Ionis Pharmaceuticals and Bactiguard and consultant from Bactiguard. APZ reports research grants from Pfizer and consultant from fees Spero Therapeutics outside of this submitted work. OB reports research grants from AstraZeneca, Pfizer, Bayer, Boehringer Ingelheim, Servier, and Amgen outside of this submitted work. RDL reports research grants from BMS, Glaxo Smith Kline, Medtronic, Portola, Bayer, Pfizer, Sanofi, Daiichi Sankyo, Merck and Boehringer Ingleheim, and consulting fees from Bayer, BMS, Glaxo Smith Kline, Portola, Merck, Boehringer Ingleheim, Daiichi Sankyo, Medtronic, Sanofi and Pfizer outside of this submitted work. The other authors have no conflict to declare.

: All five randomised clinical trials that compose the present cohort study, including their amendments for 1-year telephone follow-up, were approved by Brazil’s National Ethics Committee. Written informed consent was obtained from all participants or their proxies at the time of enrolment during hospital stay. Participants were re-consented during the first telephone call.

: Not applicable.

Free to read: This content has been made available to all.